

UCB LAUNCHES SUCCESSFUL BOND ISSUE ON NYSE EURONEXT

Released : 27 March 2013

March 27, 2013

Brussels, 27 March 2013 – NYSE Euronext (NYSE) today announced a successful €250 million bond issue on its Brussels-market by UCB, the Belgium-based global biopharmaceutical group.

UCB focuses on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With around 9.000 people in about 40 countries, the company generated revenue of €3.4 billion in 2012.

The bonds, issued by UCB on 7 years with a maturity date in 2020, have been entirely subscribed for the maximum amount of €250 million. Consequently, the subscription period was closed early. The UCB bonds, priced at a nominal of €1000, offer a coupon of 3.75% per year.

“We are delighted with the success of UCB’s bond offering on NYSE Euronext”, said Vincent Van Dessel, Chairman and CEO of NYSE Euronext Brussels. “Bonds offer businesses an attractive source of additional funding that is both flexible and efficient, and we are convinced that the bond offering encourages individual investors to return to the market.” Alain Baetens, Head of Listings Belgium at NYSE Euronext, adds: “Our goal at NYSE Euronext is to channel domestic savings back into productive investment and allow the stock exchange to steadily increase its contribution to financing the real economy.”

BNP Paribas Fortis, ING Belgium and KBC Bank acted as joint lead managers for the issue of this bond.

To celebrate the new listing, Roch Doliveux, CEO of UCB, rang the bell to open trading on NYSE Euronext’s European market. He was accompanied by members of UCB’s management team as well as Vincent Van Dessel, Chairman and CEO of NYSE Euronext Brussels and the listing team.

Information

NYSE Euronext

Jean-Yves Daxhelet

Tel.: +32 (0)2 213 13 03

E-mail: jean-yves.daxhelet@interelgroup.com

About NYSE Euronext

NYSE Euronext (NYSE) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets - the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca - represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: <http://www.nyx.com>.

Disclaimer

None of the information contained in this press release constitutes an offer, solicitation or recommendation to acquire or dispose of any security or investment or to engage in any other transaction or to provide legal, tax, accounting or investment advice or services regarding the suitability or profitability of any security or investment. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by NYSE Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. NYSE Euronext offers no view on whether investments are appropriate for you and recommends you obtain independent advice in respect of such investments. Persons wishing to trade products available on NYSE Euronext markets or wishing to offer such products to third parties (whether by way of admission to listing and/or trading of products, or otherwise) are advised, before doing so, to check their legal and regulatory position in the relevant territory and to understand the related risks. NYSE Euronext does not make any recommendations regarding the merit of any company, security or other financial product or investment identified in this press release. Similarly, NYSE Euronext does not make any recommendation regarding the purchase or sale of any company, security, financial product or investment, endorsed or sponsored by any company identified in this press release. This press release is not intended to be, and shall not constitute in any way a binding or legal agreement, or impose any legal obligation or duty on NYSE Euronext or any of its affiliates. This press release speaks only as of this date. NYSE Euronext disclaims any duty to update the information herein.

